Compass has resolved the significant issues with its financial filings, known as material weaknesses, meeting a self-imposed deadline. The disclosure generally refers to a systemic problem at a ...
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass achieved its free cash flow goal in Q2, but still records a net loss of $46.9 million. During the second quarter of 2023, Compass recorded a free cash flow of $51 million, compared to a free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results